JP2018522866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522866A5 JP2018522866A5 JP2017567060A JP2017567060A JP2018522866A5 JP 2018522866 A5 JP2018522866 A5 JP 2018522866A5 JP 2017567060 A JP2017567060 A JP 2017567060A JP 2017567060 A JP2017567060 A JP 2017567060A JP 2018522866 A5 JP2018522866 A5 JP 2018522866A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- polymorph
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 21
- 239000013078 crystal Substances 0.000 claims 20
- 239000012453 solvate Substances 0.000 claims 20
- 239000000651 prodrug Substances 0.000 claims 19
- 229940002612 prodrug Drugs 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 125000004452 carbocyclyl group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000002252 acyl group Chemical group 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 3
- 230000001568 sexual effect Effects 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 238000003419 tautomerization reaction Methods 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185334P | 2015-06-26 | 2015-06-26 | |
| US62/185,334 | 2015-06-26 | ||
| PCT/US2016/039312 WO2016210296A1 (en) | 2015-06-26 | 2016-06-24 | 4,6-pyrimidinylene derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522866A JP2018522866A (ja) | 2018-08-16 |
| JP2018522866A5 true JP2018522866A5 (enExample) | 2019-07-25 |
| JP6947651B2 JP6947651B2 (ja) | 2021-10-13 |
Family
ID=57585796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567060A Active JP6947651B2 (ja) | 2015-06-26 | 2016-06-24 | ４，６−ピリミジニレン誘導体およびこれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10695346B2 (enExample) |
| EP (1) | EP3313530B1 (enExample) |
| JP (1) | JP6947651B2 (enExample) |
| AU (1) | AU2016283105C1 (enExample) |
| WO (1) | WO2016210296A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3236959B1 (en) | 2014-12-23 | 2025-09-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| JP6861166B2 (ja) | 2015-03-27 | 2021-04-21 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
| WO2017073065A1 (ja) * | 2015-10-28 | 2017-05-04 | 公益財団法人静岡県産業振興財団 | 新規抗がん薬 |
| EP3557998B1 (en) * | 2016-12-23 | 2023-08-16 | Aquinnah Pharmaceuticals Inc. | Compouns, compositions and methods of use |
| BR112020012635A2 (pt) * | 2017-12-22 | 2020-12-01 | Ravenna Pharmaceuticals, Inc. | derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase |
| AU2018388406B2 (en) * | 2017-12-22 | 2023-07-06 | HiberCell Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| EP3728217B1 (en) | 2017-12-22 | 2023-11-15 | HiberCell, Inc. | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| GEAP202215475A (en) * | 2018-04-26 | 2022-07-11 | Pfizer Inc | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| EP3787629A4 (en) | 2018-05-02 | 2022-01-05 | Kinnate Biopharma Inc. | CYCLINE-DEPENDENT KINASE INHIBITORS |
| CA3099763A1 (en) | 2018-06-25 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| SG11202013175SA (en) | 2018-06-29 | 2021-01-28 | Kinnate Biopharma Inc | Inhibitors of cyclin-dependent kinases |
| US11773096B2 (en) | 2018-08-10 | 2023-10-03 | Yale University | Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same |
| US12281126B2 (en) | 2018-12-28 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| TW202112784A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CN113698391B (zh) * | 2020-05-21 | 2023-06-06 | 上海拓界生物医药科技有限公司 | 4-氨基嘧啶或2-氨基三嗪类化合物及其制备方法 |
| JP2023554673A (ja) * | 2020-12-21 | 2023-12-28 | ヤンセン ファーマシューティカ エヌ．ベー． | サイクリン依存性キナーゼ７（ｃｄｋ７）阻害剤としての三環式ピリミジン |
| WO2022140554A1 (en) * | 2020-12-23 | 2022-06-30 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of phosphatidylinositol-5-phosphate 4-kinase type 2 and uses thereof |
| WO2022246025A1 (en) * | 2021-05-20 | 2022-11-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors and degraders of pip4k protein |
| PE20240812A1 (es) | 2021-08-18 | 2024-04-18 | Chemocentryx Inc | Arilsulfonil(hidroxi)piperidinas como inhibidores de ccr6 |
| CN118019735A (zh) | 2021-08-18 | 2024-05-10 | 坎莫森特里克斯公司 | 作为ccr6抑制剂的芳基磺酰基化合物 |
| CN113861130A (zh) * | 2021-09-29 | 2021-12-31 | 守恒(厦门)医疗科技有限公司 | 联苯磺胺噻二唑类衍生物及其在抗肿瘤药物的应用 |
| CN113698357A (zh) * | 2021-09-29 | 2021-11-26 | 守恒(厦门)医疗科技有限公司 | 磺胺嘧啶类衍生物及其在抗肿瘤药物的应用 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2023227125A1 (zh) * | 2022-05-26 | 2023-11-30 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
| CN116903587B (zh) * | 2023-06-01 | 2024-03-22 | 三峡大学 | 一种角鲨烯环氧酶抑制剂及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1205276A (en) * | 1915-03-29 | 1916-11-21 | Robert C Sharpe | Machine or instrument for cracking nuts. |
| HUE034712T2 (hu) * | 2003-12-25 | 2018-02-28 | Nippon Shinyaku Co Ltd | Amidszármazék és gyógyszer |
| WO2007076474A1 (en) | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| WO2008079460A2 (en) * | 2006-09-05 | 2008-07-03 | Emory University | Tyrosine kinase inhibitors for prevention or treatment of infection |
| WO2010009155A2 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Fused heterocyclyc inhibitor compounds |
| RU2011137399A (ru) * | 2009-02-12 | 2013-03-20 | Астеллас Фарма Инк. | Гетероциклическое производное |
| CA2784807C (en) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| CN102406644A (zh) * | 2010-09-20 | 2012-04-11 | 北大方正集团有限公司 | 芳基脲衍生物用于制备治疗移植排斥药物的新用途 |
| CN102408408A (zh) * | 2010-09-20 | 2012-04-11 | 北大方正集团有限公司 | 具有抗肿瘤作用的芳基脲衍生物 |
| CN102406646B (zh) * | 2010-09-20 | 2015-09-09 | 北大方正集团有限公司 | 芳基脲衍生物用于制备治疗移植排斥药物的用途 |
| US9382239B2 (en) * | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
| WO2013154778A1 (en) | 2012-04-11 | 2013-10-17 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN103242341B (zh) | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用 |
| CN104177363B (zh) | 2013-05-24 | 2018-06-05 | 江苏先声药业有限公司 | 双环杂环胺类Hedgehog信号通路抑制剂 |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| CN105849099B (zh) * | 2013-10-18 | 2020-01-17 | 达纳-法伯癌症研究所股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的多环抑制剂 |
| JP6879740B2 (ja) * | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| AU2016276963C1 (en) * | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| HK1254469A1 (zh) | 2015-06-26 | 2019-07-19 | Dana Farber Cancer Institute, Inc. | 稠合双环嘧啶衍生物及其用途 |
-
2016
- 2016-06-24 US US15/737,535 patent/US10695346B2/en active Active
- 2016-06-24 JP JP2017567060A patent/JP6947651B2/ja active Active
- 2016-06-24 WO PCT/US2016/039312 patent/WO2016210296A1/en not_active Ceased
- 2016-06-24 AU AU2016283105A patent/AU2016283105C1/en not_active Ceased
- 2016-06-24 EP EP16815401.1A patent/EP3313530B1/en active Active
-
2020
- 2020-06-11 US US16/899,412 patent/US20210315894A9/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522866A5 (enExample) | ||
| JP2018522867A5 (enExample) | ||
| JP2019527682A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| JP6806562B2 (ja) | ｅＩＦ２α経路の調節因子 | |
| JP6342805B2 (ja) | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 | |
| JP5576485B2 (ja) | 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール | |
| JP2019524883A5 (enExample) | ||
| JP2018515434A5 (enExample) | ||
| ES2594378T3 (es) | Derivados de la bencilidenoguanidina y uso terapéutico para el tratamiento de enfermedades por mal plegamiento proteico | |
| BR112020008817B1 (pt) | Compostos moduladores da via de estresse integrada referência cruzada a pedidos relacionados | |
| Di Mola et al. | Structure–activity relationship study of arbidol derivatives as inhibitors of chikungunya virus replication | |
| BR112020008836A2 (pt) | Moduladores da via de estresse integrada | |
| EA200970670A1 (ru) | Производные 3-амино-пирроло[3,4-c]пиразол-5(1h,4h,6h)-карбальдегида в качестве ингибиторов ркс | |
| JP2016509047A5 (enExample) | ||
| JP2014510774A5 (enExample) | ||
| CN105246887B (zh) | 香豆素衍生物以及用于治疗过度增生性疾病的方法 | |
| JP2010510237A5 (enExample) | ||
| JP2017524733A5 (enExample) | ||
| JP2016507502A5 (enExample) | ||
| WO2018075959A4 (en) | Methods using hdac11 inhibitors | |
| JP2017537886A5 (enExample) | ||
| JP2020516616A5 (enExample) | ||
| JP2016525104A5 (enExample) | ||
| JP2025118609A (ja) | Ｎｕｒｒ１受容体調節因子 |